JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
126.83
+0.17 (+0.13%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close126.66
Open126.88
Bid126.75 x 100
Ask127.44 x 100
Day's Range125.78 - 127.30
52 Week Range122.15 - 148.32
Volume7,501,870
Avg. Volume8,031,553
Market Cap340.239B
Beta0.59
PE Ratio (TTM)267.57
EPS (TTM)0.47
Earnings DateJul 17, 2018
Forward Dividend & Yield3.36 (2.57%)
Ex-Dividend Date2018-02-26
1y Target Est149.05
Trade prices are not sourced from all markets
  • Johnson & Johnson’s Revenues Continued to Rise in 1Q18
    Market Realist13 hours ago

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.

  • Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
    Market Realist18 hours ago

    Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings

    Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.

  • Motley Fool18 hours ago

    Johnson & Johnson's Top-Line Growth Isn't What It Seems

    The company’s double-digit growth comes with some caveats.

  • Geron Corporation: The Clock Is Ticking
    Motley Fool20 hours ago

    Geron Corporation: The Clock Is Ticking

    Geron's stock has been a magnet for short-sellers, but the long thesis remains intact.

  • Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
    Market Realist20 hours ago

    Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall

    As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.

  • Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
    Market Realist21 hours ago

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

  • Reutersyesterday

    British businesses embrace profits with a purpose

    Like many combat veterans, Steve Hammond struggled for years after returning to civilian life, battling physical injuries that made it difficult to find a job and left him contemplating suicide. Now the 61-year-old father of two is thriving as a team leader with Britain's Bravest Manufacturing Company (BBMC), one of a growing number of socially-minded companies providing jobs for people marginalised from the traditional workforce. "It gives people with a disability or mental health issues a purpose in life," Hammond, who was wounded in the Falklands War, told the Thomson Reuters Foundation.

  • 3 Things You Should Know About Today's Top Entrepreneurs
    Motley Fool2 days ago

    3 Things You Should Know About Today's Top Entrepreneurs

    A new wave of innovation will change several of America's most established industries. Here are three important takeaways for investors.

  • Motley Fool2 days ago

    Johnson & Johnson's First-Quarter 2018 Earnings Review

    We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.

  • Barrons.com3 days ago

    [$$] Square, eBay, and the Future of Money

    Earnings per share were higher despite a higher tax rate and a lower contribution from other income. What we didn’t like about the first quarter: 1) the pharma mix was not optimal, as key drugs Actelion, Darzalex, and Xarelto all missed our estimate. U.S. Remicade was down 16% Y/Y, in line with our estimate, but we were hoping for better.

  • 4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings
    InvestorPlace4 days ago

    4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings

    After a spell of high volatility driven by uncertainty over global trade policy and the threat of rise in prices of essential commodities, Wall Street is looking for some respite in the upcoming earnings season. Given the positive trend, investing in blue-chip stocks that are likely to make the most of the earnings season seems judicious. This is because such stocks are positioned to report impressive earnings results as they mostly have a strong balance sheet and solid cash flow.

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks4 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
    Zacks4 days ago

    J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

    Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

  • AbbVie And Other Great Pharma And Biotech Income Stocks
    Simply Wall St.4 days ago

    AbbVie And Other Great Pharma And Biotech Income Stocks

    Pharmaceutical and biotech stocks are rarely seen as effective dividend stocks. Although drugs are also relatively non-cyclical these stocks are often impacted by ever-changing regulatory environment and the strength ofRead More...

  • Dow 30 Stock Roundup: AmEx, Goldman, IBM, JNJ, P&G, UNH Earnings Impress
    Zacks4 days ago

    Dow 30 Stock Roundup: AmEx, Goldman, IBM, JNJ, P&G, UNH Earnings Impress

    The Dow experienced a particularly volatile week as earnings results took center stage.

  • CNBC4 days ago

    Johnson & Johnson is betting on vision care and expanding beyond contacts

    J&J has added surgical products and a contact subscription service to its lineup of Acuvue contact lenses.

  • CNBC4 days ago

    Johnson & Johnson is betting on vision care and expanding beyond contacts

    J&J has added surgical products and a contact subscription service to its lineup of Acuvue contact lenses.

  • TheStreet.com4 days ago

    P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

    issues were still top of mind to just about everyone as investors continued to drive the stock down as well. It's tough for some investors to find a positive view of the Seattle-based coffee house company. It's been trading sideways for close to three years, producing a 2% return over the last 12 months compared with 15% for the S&P and a somewhat pricey 21 times P/E multiple for a food and beverage company, all of which make an unappetizing menu choice for investors, never mind the company's moral and ethical dilemmas, says Stephen Guilfoyle.

  • Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings
    Zacks5 days ago

    Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings

    Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.

  • 3 Drugs That Are Moving the Needle at Johnson & Johnson
    Motley Fool5 days ago

    3 Drugs That Are Moving the Needle at Johnson & Johnson

    Johnson & Johnson owes a lot of its early success this year to rapidly growing sales of three key products.

  • Barrons.com5 days ago

    After the Bell: Dow Drops 38 Points Because…IBM

    The major equity indexes barely moved today, as a postearnings drop from International Business Machines (IBM) was canceled out by gains from Textron (TXT), Intuitive Surgical (ISRG), and others. Ultimately, it shows once again that it's as much a market of stocks as it is a stock market. The Dow Jones Industrial Average dropped 38.56 points, or 0.2%, to 24,748.07, while the S&P 500 ticked up 0.1% to 2708.64, and the Nasdaq Composite advanced 0.2% to 7295.24.

  • Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'
    CNBC6 days ago

    Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'

    "I'm not on board with just about anything that he does," Gov. Matt Bevin said of Kentucky Attorney General Andy Beshear.

  • Reuters6 days ago

    Kentucky accuses J&J of contributing to opioid epidemic

    Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction. The lawsuit by Kentucky Attorney General Andy Beshear was his fifth to date seeking to hold a drug manufacturer or distributor responsible for its role in the national opioid epidemic.

  • MarketWatch6 days ago

    IBM and J&J stocks cut 100 points from Dow industrials in early trading

    The Dow Jones Industrial Average on Wednesday morning was wrestling with sharp declines in IBM and Johnson & Johnson. Shares of International Business Machines Corp. were off 7.2%, or about $11.50, which equates to a drop of about 80 points, while J&J's stock was contributing a further 24-point retreat in the benchmark, down 2.7%, or about $3.50, in recent action. Overall, the Dow was still managing to rise by about 24 points, or less than 0.1%, at 24,802, with J&J and IBM's tumble slightly offset by gains in Home Depot Inc. Caterpillar Inc. and Boeing Co. 's stocks.

  • Kentucky Governor Bevin: I'm not on board with JNJ opioid...
    CNBC Videos6 days ago

    Kentucky Governor Bevin: I'm not on board with JNJ opioid...

    Kentucky Governor Matt Bevin discusses his state District Attorney suing Johnson & Johnson for contributing to the opioid epidemic through deceptive marketing.